Response by baseline BCR-ABL mutation analysis of patients with imatinib-resistant and -intolerant CML-AP at 8 months' follow-up
| . | Total* . | Patients with MaHR . | Patients with MCyR . |
|---|---|---|---|
| No mutation, no. (%) | 40 (40) | 22/40 (55) | 15/40 (38) |
| Any mutation, no. (%) | 60 (60) | 44/60 (73) | 18/60 (30) |
| P-Loop,† n (%) | 30 (30) | 22/30 (73) | 7/30 (23) |
| A-Loop,‡ n (%) | 7 (7) | 6/7 (86) | 4/7 (57) |
| Other regions, no. (%) | 24 (24) | 17/24 (71) | 8/24 (33) |
| Mutations documented in at least 2 patients, no. patients | |||
| M244V | 5 | 4 | 2 |
| L248V | 3 | 3 | 1 |
| G250E | 9 | 6 | 1 |
| Y253H | 6 | 5 | 2 |
| E255K | 6 | 4 | 0 |
| E255V | 2 | 2 | 1 |
| T315I | 5 | 0 | 0 |
| F317L | 4 | 4 | 0 |
| M351T | 6 | 3 | 1 |
| E355G | 4 | 2 | 2 |
| F359C | 2 | 2 | 2 |
| F359V | 7 | 5 | 1 |
| V379I | 4 | 3 | 2 |
| A397P | 2 | 2 | 1 |
| E459K | 3 | 1 | 3 |
| . | Total* . | Patients with MaHR . | Patients with MCyR . |
|---|---|---|---|
| No mutation, no. (%) | 40 (40) | 22/40 (55) | 15/40 (38) |
| Any mutation, no. (%) | 60 (60) | 44/60 (73) | 18/60 (30) |
| P-Loop,† n (%) | 30 (30) | 22/30 (73) | 7/30 (23) |
| A-Loop,‡ n (%) | 7 (7) | 6/7 (86) | 4/7 (57) |
| Other regions, no. (%) | 24 (24) | 17/24 (71) | 8/24 (33) |
| Mutations documented in at least 2 patients, no. patients | |||
| M244V | 5 | 4 | 2 |
| L248V | 3 | 3 | 1 |
| G250E | 9 | 6 | 1 |
| Y253H | 6 | 5 | 2 |
| E255K | 6 | 4 | 0 |
| E255V | 2 | 2 | 1 |
| T315I | 5 | 0 | 0 |
| F317L | 4 | 4 | 0 |
| M351T | 6 | 3 | 1 |
| E355G | 4 | 2 | 2 |
| F359C | 2 | 2 | 2 |
| F359V | 7 | 5 | 1 |
| V379I | 4 | 3 | 2 |
| A397P | 2 | 2 | 1 |
| E459K | 3 | 1 | 3 |